Equity

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Equity

Equity

As of December 31, 2022 and 2021, the Company had reserved shares of common stock for issuance in connection with the following:

	December 31,
	2022	2021
Options to purchase common stock	4,034,287	3,949,943
Restricted stock units	2,807,981	309,530
Shares available for future grant under the 2021 Plan	3,151,824	5,103,772
Shares available for future grant under the ESPP	1,179,902	800,000
Total	11,173,994	10,163,245

Preferred Stock

Effective June 14, 2021, in connection with the closing of the Company’s IPO, the Company’s Board of Directors is authorized to issue up to 10,000,000 shares of preferred stock, $0.01 par value per share, in one or more series. The Company's Board of Directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. As of December 31, 2022 and 2021, no shares of preferred stock were issued or outstanding.

Common Stock

As of December 31, 2022 and 2021, the Company had authorized 400,000,000 shares of voting common stock, $0.01 par value per share. Each holder of the Company's common stock is entitled to one vote for each share on all matters to be voted upon by the stockholders and there are no cumulative rights. Subject to any preferential rights of any outstanding preferred stock, holders of the Company's common stock are entitled to receive ratably the dividends, if any, as may be declared from time to time by the Board of Directors out of legally available funds. If there is a liquidation, dissolution, or winding up of the Company, holders of the Company's common stock would be entitled to share in the Company's assets remaining after the payment of liabilities and any preferential rights of any outstanding preferred stock. The rights, preferences, and privileges of the holders of the Company's common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock which the Company may designate and issue in the future.